Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Detection of SARS-CoV-2 Virus by Triplex Enhanced Nucleic Acid Detection Assay (TENADA)

  • Aviñó, Anna
  • Cuestas-Ayllón, Carlos
  • Gutiérrez-Capitán, Manuel
  • Vilaplana, Lluisa
  • Grazu, Valeria
  • Noé, Véronique
  • Balada, Eva
  • Baldi, Antonio
  • Félix, Alex J.
  • Aubets, Eva
  • Valiuska, Simonas
  • Domínguez, Arnau
  • Gargallo, Raimundo
  • Eritja, Ramon
  • Marco, M.-Pilar
  • Fernández-Sánchez, César
  • Martínez de la Fuente, Jesús
  • Ciudad, Carlos J.
SARS-CoV-2, a positive-strand RNA virus has caused devastating effects. The standard method for COVID diagnosis is based on polymerase chain reaction (PCR). The method needs expensive reagents and equipment and well-trained personnel and takes a few hours to be completed. The search for faster solutions has led to the development of immunological assays based on antibodies that recognize the viral proteins that are faster and do not require any special equipment. Here, we explore an innovative analytical approach based on the sandwich oligonucleotide hybridization which can be adapted to several biosensing devices including thermal lateral flow and electrochemical devices, as well as fluorescent microarrays. Polypurine reverse-Hoogsteen hairpins (PPRHs) oligonucleotides that form high-affinity triplexes with the polypyrimidine target sequences are used for the efficient capture of the viral genome. Then, a second labeled oligonucleotide is used to detect the formation of a trimolecular complex in a similar way to antigen tests. The reached limit of detection is around 0.01 nM (a few femtomoles) without the use of any amplification steps. The triplex enhanced nucleic acid detection assay (TENADA) can be readily adapted for the detection of any pathogen requiring only the knowledge of the pathogen genome sequence.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Clinical performance evaluation of a rapid real-time PCR assay for monkeypox diagnosis: a retrospective and comparative study

  • Peris, María Paz
  • Clusa, Laura
  • Alonso, Henar
  • Escolar, Cristina
  • Fortuño, Blanca
  • Rezusta, Antonio
  • Milagro, Ana
In an increasingly globalized and interconnected world, the outbreak of an infectious disease in one country can become a worrying health emergency for the whole world. A current example is the 2022 monkeypox virus (mpox) outbreak affecting multiple areas across the world. In this context, strategies to interrupt transmission as soon as possible by identifying cases, clusters, and sources of infection should be developed around the world to prevent these crises. The aim of this retrospective and collaborative study was to perform external clinical validation of the VIASURE monkeypox virus real-time PCR detection kit (CerTest Biotec, Spain) with ready-to-use reagents designed for the rapid detection of mpox. A total of 165 samples with suspected infection were used for this analysis. The standard procedures of the clinical microbiology laboratory of the Miguel Servet University Hospital, using the RealStar Orthopoxvirus PCR kit v1.0 (Altona Diagnostics) and bidirectional Sanger sequencing (STAB VIDA, Caparica, Portugal), were considered reference techniques. Furthermore, a subset of 67 mpox-negative samples and 13 mpox-positive samples were routinely tested for clinical diagnosis of other rash/ulcerative pathologies. Accuracy testing resulted in appropriate clinical validation values, as follows: sensitivity, 1 (95% confidence interval [CI], 0.97 to 1); specificity, 1 (95% CI, 0.98 to 1); positive predictive value, 1 (95% CI, 0.93 to 1); negative predictive value, 1 (95% CI, 0.95 to 1). The strength of agreement between assays was almost perfect. The added value is the useful support for the specific diagnosis of mpox infections due to the diagnostic specificity data obtained.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Novel protocol for the transcriptomic analysis of endothelial extracellular vesicles in atherosclerosis

  • Saenz-Pipaon, Goren
  • Cenarro, Ana
  • Zazpe, Jon
  • Goñi-Oloriz, Miriam
  • Martinez-Aguilar, Esther
  • Machado, Florencio J.D.
  • Marchese, Francesco P.
  • Orbe, Josune
  • López-Andrés, Natalia
  • Civeira, Fernando
  • Paramo, Jose A.
  • Lara-Astiaso, David
  • Roncal, Carmen
Introduction: Despite the key role of the endothelium in atherosclerosis, there are no direct techniques for its analysis. The study of extracellular vesicles of endothelial origin (EEVs), might lead to the identification of molecular signatures and early biomarkers of atherosclerosis. The aim of this work was to set up the methods for EEVs separation and transcriptomic analysis. Methods: We adapted an antibody-magnetic-bead based immunocapture protocol for plasma EEVs separation from control (G1), subclinical atherosclerosis (G2) and peripheral artery disease subjects (PAD) (G3), and modified an ultra-low input RNASeq method (n = 5/group). By bioinformatics analysis we compared the transcriptome of plasma EEVs with that of human aortic endothelial cells (TeloHAECs), and then, searched for differentially expressed genes (DEG) among EEVs of G1, G2 and G3. From those DEG, UCP2 was selected for further validation in plasma EVs (qPCR), and in vitro, in stimulated TeloHAECs (IL-1β, TNFα, oxLDL and hypoxia). Results: The RNASeq analysis of plasma EEVs rendered 1667 genes enriched in transcripts expressed by TeloHAECs (NES: 1.93, p adjust = 1.4e−73). One hundred seventy DEGs were identified between G2 vs G1, and 180 between G3 vs G1, of which 17 were similarly expressed in G2 and G3 vs control, including UCP2. IL-1β and TNFα (10 ng/mL, p < 0.05), hypoxia (1% O2, p = 0.05) and oxLDL (100 μg/mL, p = 0.055) reduced UCP2 expression in TeloHAECs. Conclusions: We set up a protocol for EEVs separation and sequencing that might be useful for the identification of early markers of endothelial dysfunction in atherosclerosis. Introducción: A pesar del papel clave del endotelio en la aterosclerosis, no existen técnicas directas para su análisis. El estudio de las vesículas extracelulares de origen endotelial (EEV) podría facilitar la identificación de firmas moleculares y biomarcadores tempranos de aterosclerosis. El objetivo de este trabajo fue establecer los métodos para la separación de EEV y su análisis transcriptómico. Métodos: Adaptamos un protocolo de inmunocaptura con anticuerpos y microesferas magnéticas para la separación de las EEV del plasma de sujetos control (G1), con aterosclerosis subclínica (G2) y con enfermedad arterial periférica (G3), y modificamos un método de RNASeq para su análisis transcriptómico (n = 5/grupo). Comparamos el transcriptoma de las EEV plasmáticas con el de células endoteliales de aorta humana (TeloHAEC) e identificamos genes diferencialmente expresados (DEG) entre los grupos de pacientes, incluyendo UCP2, validado en EV plasmáticas (qPCR) e in vitro, en TeloHAECs tratadas con IL-1β, TNF-α, oxLDL e hipoxia. Resultados: El RNASeq de las EEV plasmáticas detectó 1.667 genes enriquecidos en transcritos expresados por las TeloHAECs (NES: 1,93, ajuste p = 1,4e−73). Se identificaron 170 DEG entre los grupos G2 vs. G1 y 180 entre G3 vs. G1, de los cuales 17 se expresaron de forma similar en G2 y G3 vs. control, incluyendo UCP2. El tratamiento con IL-1β y TNF-α (10 ng/ml, p < 0,05), hipoxia (1% O2, p = 0,05) y oxLDL (100 μg/ml, p = 0,055) redujo la expresión de UCP2 en las TeloHAEC. Conclusiones: Hemos puesto a punto un protocolo para la separación y la secuenciación de EEV que podría ser útil para la identificación de marcadores tempranos de disfunción endotelial en aterosclerosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers

  • Oliván-Blázquez, Bárbara
  • Bona-Otal, Marta
  • Méndez-López, Fátima
  • Lerma-Irureta, David
  • García-Izuel, Paula
  • Ibáñez-Ruiz, Jesús
  • Montolío, Alberto
  • Ruiz-Herreros, María
  • Godino, Javier
  • Jimeno-Beltran, Beatriz
  • Encabo-Berzosa, María del Mar
  • Arenaz, Izaskun
  • Medel-Martínez, Ana
  • Casado-Vicente, Verónica
  • Coiras, Mayte
  • Tellería-Orriols, Carlos
  • Schoorlemmer, Jon
  • Magallón-Botaya, Rosa
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups: PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12–24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16brightCD56− cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Combination of exhaled volatile organic compounds with serum biomarkers predicts respiratory infection severity

  • Esteban, Patricia
  • Letona-Gimenez, Santiago
  • Domingo, Maria Pilar
  • Morte, Elena
  • Pellejero-Sagastizabal, Galadriel
  • Encabo, Maria del Mar
  • Ramírez-Labrada, Ariel
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño, José Ramón
  • Galvez, Eva M.
Objective. During respiratory infections, host-pathogen interaction alters metabolism, leading to changes in the composition of expired volatile organic compounds (VOCs) and soluble immunomodulators. This study aims to identify VOC and blood biomarker signatures to develop machine learning-based prognostic models capable of distinguishing infections with similar symptoms. Methods. Twenty-one VOCs and fifteen serum biomarkers were quantified in samples from 86 COVID-19 patients, 75 patients with non-COVID-19 respiratory infections, and 72 healthy donors. The populations were categorized into severity subgroups based on their oxygen support requirements. Descriptive and statistical analyses were conducted to assess group differentiation. Additionally, machine learning classifiers were developed to predict disease severity in both COVID-19 and non-COVID-19 patients. Results. VOC and biomarker profiles differed significantly among groups. Random Forest models demonstrated the best performance for severity prediction. The COVID-19 model achieved 93% accuracy, 100% sensitivity, and 89% specificity, identifying IL-6, IL-8, thrombomodulin, and toluene as key severity predictors. In non-COVID-19 patients, the model reached 89% accuracy, 100% sensitivity, and 67% specificity, with CXCL10 and methyl-isobutyl-ketone as key markers. Conclusion.VOCs and serum biomarkers differentiated HD, COVID-19, and non-COVID-19 patients, and enabled the development of high-performance severity prediction models. While promising, these findings require validation in larger independent cohorts.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Expression Profiles of Exosomal miRNAs in Gaucher Patients and Their Association With Severity of Bone Involvement

  • Serrano-Gonzalo, Irene
  • López de Frutos, Laura
  • Sancho-Albero, Maria
  • Roca-Espiau, Mercedes
  • Köhler, Ralf
  • Giraldo, Pilar
Bone manifestations are one of the most prevalent complications in patients with Gaucher disease (GD). Bone involvement is evaluated by using imaging methods, and there are different scores to assess its severity. However, there are no biomarkers that allow us to predict these manifestations. In recent years, several miRNAs have been associated with bone involvement and postulated as excellent bioavailable biomarkers. This study aims to identify a miRNA expression profile from plasma exosomes and to associate it with the severity of bone involvement in patients with GD. This study included 60 untreated patients with GD with bone involvement, who were classified according to the S‐MRI score into three groups: mild disease (MiBD; S‐MRI < 5), moderate disease (MoBD; S‐MRI: 5–11), or severe disease (SBD; S‐MRI > 11). Plasma exosomes were purified, and miRNAs were extracted and identified by next‐generation sequencing (NGS) technology. Differentially expressed miRNAs were validated by droplet digital PCR (ddPCR). In the patients' groups classified by S‐MRI, the median ages (Q1–Q3) were: MiBD 19.0 (4.00–40.00), MoBD 40.5 (28.25–56.00), and SBD 37.5 (31.25–47.00) years. When comparing groups, we found 12 differentially expressed exosomal miRNAs. After validation, four miRNAs were identified as differentially expressed: hsa‐miR‐127‐3p, hsa‐miR‐184, hsa‐miR‐197‐3p, and hsa‐miR‐660‐5p. Notably, hsa‐miR‐127‐3p, hsa‐miR‐660‐5p, and hsa‐miR‐184 were correlated with the presence of infarcts, necrosis, and the degree of infiltration into the spine, pelvis, and femur. These three miRNAs could serve as bioavailable biomarkers to assess bone disease in GD, and further revalidation with a higher number of patients.